Total weight loss did not increase for patients who took semaglutide before having BMS, suggesting that a surgery-first strategy could lead to better outcomes, according to a study by researchers at Mass General Brigham. The study could help inform conversations between providers and patients who are considering whether to try weight-loss medications or surgery first.
Previous studies have found that taking semaglutide after weight-loss surgery may be effective to help lose more weight or maintain weight, although additional research is needed. The effectiveness of taking semaglutide before weight-loss surgery was unknown.
Researchers studied whether taking semaglutide before bariatric surgery could help patients with obesity and metabolic disease lose weight. But the retrospective study of 350 patients revealed that taking semaglutide before bariatric surgery did not improve overall weight loss or safety outcomes compared to surgery alone.
"Many people are familiar with the new GLP-1 medicines that are available. These drugs are good options for patients to consider, and they can be used in combination with surgery," said senior author, Dr Eric G Sheu, of the Laboratory for Surgical and Metabolic Research and chief of the Section of Bariatric and Foregut Surgery at Brigham and Women's Hospital. "You might expect patients to lose more weight if they take a medication prior to surgery. But we were surprised to find that the group of patients who went on medicines first and then had surgery actually had the same combined total weight loss. This contrasts with previous studies that have found that taking semaglutide after surgery can further help patients lose weight."
Using data from the Brigham's Center for Weight Management and Wellness, the researchers retrospectively identified 182 patients over the last seven years who were treated with semaglutide before undergoing bariatric surgery. They matched each of the patients to another patient with similar health characteristics that underwent the same type of surgery without previously taking the drugs.
The study team compared the amount of weight lost, health outcomes and safety outcomes between the groups.
The researchers found that patients who took the semaglutide before surgery had a higher percentage of total weight-loss at three months than patients who had weight-loss surgery only. But the surgery-only group rapidly caught up, and total weight loss for the group that had received semaglutide before surgery plateaued at the same percentage lost at the six-, nine-, and 12-month marks.
The researchers also found that the number and degree of safety events were similar for both groups, with no significant difference in major postoperative complications, including bleeding, leakage, infection, re-operation, re-admission or operative time. Health outcomes were also comparable between the groups, with similar levels of diabetes remission after one year.
"We are trying to figure out the best timing for these strategies to maximise their effectiveness and safety. When a patient should start the medicine, when they should stop taking it before surgery, and when they should have the surgery are things that still need to be evaluated," said Sheu. "We also need to understand if the type of bariatric surgery matters for how patients respond to the medicines."
Prospective studies will be an important tool for answering these questions in the future.
"We will need to conduct more research to answer the remaining questions, but there's at least a suggestion that the most effective weight-loss strategy isn't as simple as 1 + 1 = 2," Sheu said. "The order of strategies may be key."
The findings were featured in the paper, ‘'Neo-adjuvant' semaglutide reduces weight loss with bariatric surgery and does not improve overall outcomes’, published in JAMA Surgery. To access this paper, please click here (log-in maybe required)
Commentaires